Skip to main content

Webinar: Preclinical antibody discovery by Alloy Therapeutics (EN)

Antibody-based therapeutics represent one of the largest and fastest growing drug modalities in the world. In 2019, antibody-based therapeutics accounted for over 140 billion dollars annual sales worldwide and represented five of the top 10 selling therapeutics. Today, hundreds of companies worldwide are developing antibody-based therapies with the goal of improving outcomes for patients in need.

In this webinar, Alloy Therapeutics, a leader in human antibody-based drug discovery platform technologies and discovery services, will share its perspectives on best practices for preclinical antibody drug discovery, review Alloy’s current offerings, and provide an open Q&A for all participants.

Participation is free, however registration is required before February 17, 2021.

Program

15:00

Welcome

15:05

Alloy Therapeutics

Heather Schwoebel, Senior Vice President of BD, Head of Platform Licensing
Piotr Bobrowicz, Chief Technology Officer

15:50

Q & A

16:00

Networking 1:1

Our partner